R&D | March 10, 2026
UK pushes space-made medicines from orbit to patients with new support package
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
Built on the Percept Platform and enhanced with BrainSense technology, the system can adjust stimulation levels in real time, responding to brain signals without manual intervention
The decision marks a pivotal moment for the Massachusetts-based biotech giant
The program provides pharmaceutical manufacturers with auditable, primary emissions data and verified proof of a 30% CO? reduction across DFE Pharma’s lactose portfolio
The revenues this quarter are in line with the outlook we envisaged for the year
HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors
The state-of-the-art commercial production plant will be built on a 95-acre site in Saarlouis, acquired at the end of 2024
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
Gastrointestinal conditions affect millions across the UK, yet research in the field has often been fragmented, slow, or under-resourced
Subscribe To Our Newsletter & Stay Updated
